



Hamlet BioPharma proposes a directed new share issue to finance continued development and commercialization based on three positive Phase II studies

Lund, 18 July 2025, Hamlet BioPharma, an innovative pharmaceutical company that develops new therapies against cancer and infections, announces today that the company proposes to raise capital through a directed new issue of B shares with associated warrants (so-called units). A unit consists of a B share with a short and a longer warrant. The issue initially adds just over SEK 30 million and, if the warrants are fully exercised, can provide a further capital injection of a total of approximately SEK 110 million, which means that the company can add up to SEK 140 million in new capital in total. The issue is aimed at approximately 20 external investors and the subscription price per unit is SEK 4.30. The subscription price corresponds to the average volume-weighted share price during 30 trading days of SEK 4,30. The subscription price for the short option that runs for 12 months is SEK 6 per share and the subscription price for the long option that runs for 30 months is SEK 10 per share. Dilution after full subscription is calculated at just over 10%. Hamlet BioPharma has received binding subscription commitments from all external investors. The directed share issue is subject to approval from an extraordinary general meeting. Notice of the general meeting with the board's full proposal will be published shortly.

Through the directed new issue, Hamlet BioPharma will initially receive just over SEK 30 million with the possibility of a further total of approximately SEK 110 million before deductions for transaction costs, which are expected to be low as the company carries out the directed issue on its own merits. The external investors in the directed issue are carried out by a total of 20 investment companies and family offices, among them Trinit AB, Oakwood Holding AB, JEQ Capital AB, Jinderman & Partners AB, Kristian Kierkegaard Holding AB, Östen Carlsson and Henrik Sundin.

"We are extremely grateful for the strong investor support for Hamlet BioPharma and our portfolio of drug candidates. So far, the company has invested just over SEK 220 million and delivered three documented successful Phase II studies, including a cancer project in fast-track for market approval in the USA. The proposed issue gives us an initial capital injection of SEK 30 million with the possibility of an additional SEK 110 million. We are humbly grateful for the trust in the company and will continue to use our capital efficiently for the optimal development and commercialization of our drugs. In parallel, we continue dialogues with several actors about potential collaborations and partnerships that can accelerate the projects", comments

Catharina Svanborg, CEO.

Background and purpose

The capital acquisition takes place after a successful meeting with the U.S. Food and Drug Administration (FDA) on June 24. In the meeting with the FDA, the process for the implementation of the phase III study for market approval of Alpha 1H, treatment of bladder cancer, was discussed. Hamlet BioPharma has two more drug candidates, a new concept for the treatment of recurrent bacterial infections and the treatment of bladder pain, with positive Phase II studies. The targeted issue is primarily to finance continued development and commercialization of the company's three indications with positive Phase II studies, namely of a drug candidate, Alpha 1H, used for the treatment of bladder cancer, in the Fast track FDA process for Phase III approval in the United States. Hamlet BioPharma intends to continue investing in clinical studies and preparations for market approval, especially for the three drug candidates that have documented successful Phase II studies, i.e.

- Alpha1H – treatment of bladder cancer,
- Immunotherapy as an alternative to antibiotic treatment of recurrent urinary tract infections, as well as
- Immunotherapy against severe pain conditions - treatment of severe pain in the bladder.

Deviation from shareholders' pre-emptive rights

The directed issue is proposed to be carried out with a deviation from the shareholders' pre-emptive right. Prior to the directed issue, the board has made an overall assessment and carefully considered the possibility of raising capital through a new issue with preferential rights for the company's existing shareholders. The board believes that the reasons for deviating from the shareholders' preferential right are:

- to ensure funding for continued commercialization and development of three documented successful Phase II studies, including a cancer project in fast-track for market approval in the USA and a new concept for infection treatment,
- to diversify and strengthen the company's shareholder base with investment companies and family office investors in order to strengthen the liquidity of the company's share,
- that a directed issue has a significantly higher probability of being successful as it is known that the company's main owner, who over the years has invested a total of approximately 30 million in the company, does not have the financial opportunity to participate in a rights issue,
- that the execution of a directed new issue can take place at a significantly lower cost and with less complexity than a rights issue, in particular because the company carries out the capital acquisition on its own merits, and
- that a rights issue would take longer to complete which, especially under the current market situation, would entail an exposure to potential market volatility.

The board considers that the subscription price is market-based in such a way that it reflects prevailing market conditions and investor demand. The subscription price corresponds to the average volume-weighted share price during 30 trading days (until 17 July 2025) of SEK 4.30.

In light of the above, the board has made the assessment that a targeted new issue of B shares with warrants, so-called units, with deviation from the shareholders' preferential right, is the most advantageous option for Hamlet BioPharma to carry out the capital acquisition. The issue is subject to approval at an extraordinary general meeting. A notice with a complete proposal from the board will come shortly during July-August 2025.

This disclosure contains information that Hamlet BioPharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 18-07-2025 14:58 CET.

For further information, please contact

Catharina Svanborg, CEO, Hamlet BioPharma AB, +46 709 42 65 49,

catharina.svanborg@hamletpharma.com

Jakob Testad, CFO, Hamlet BioPharma AB, +46 70 84 84 210,

jakob.testad@hamletbiopharma.com